FDA delays decision on Savara’s molgramostim beyond Nov. 22 target date
SVRA•The FDA will miss its Nov. 22, 2026, target date for a decision on Savara’s molgramostim inhalation solution application. The review is ongoing, and no revised action date has been set.
1. Review remains ongoing
The FDA will miss the Nov. 22, 2026, target action date for Savara’s biologics license application for molgramostim inhalation solution, which targets autoimmune pulmonary alveolar proteinosis. The review remains ongoing, with no revised action date set.




